ToxRefDB v2.1:更新了毒性参考数据库中的精选的体内研究数据.
Madison Feshuk1, Lori Kolaczkowski2, Sean Watford3
1Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, Washington, DC, United States.
Frontiers in toxicology
|September 27, 2023
概括
毒性参考数据库 (ToxRefDB) 现在包括在编译错误后恢复的数据. 这一更新增强了它对化学安全评估和毒理学研究的实用性.
科学领域:
- 毒理学 毒理学 毒理学
- 环境健康 环境健康
- 化学安全 化学安全
背景情况:
- 毒性参考数据库 (ToxRefDB) 汇编了1100多种化学品的体内研究数据.
- 它包括研究设计,化学物质暴露,剂量和观察到的影响的细节.
研究的目的:
- 在ToxRefDB v2.0.0 中解决和纠正编译错误.
- 恢复无意中遗漏的效果数据并提高数据库的准确性.
主要方法:
- 更新的重点是恢复和纠正数据,而不是添加新的研究.
- 审查了现有的数据编译流程,以纠正错误.
主要成果:
- 在ToxRefDB v2.0中导致遗漏效果数据的编译错误已解决.
- ToxRefDB v2.1 现在包含了完整的恢复数据集.
结论:
- 修正后的ToxRefDB v2.1增强了它作为精心策划的体内毒理学信息资源的价值.
- 这个改进的资源支持体外查,回顾性分析和预测性毒理学.
更多相关视频
相关概念视频
Pharmacovigilance
876
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
876
In-vitro Mutagenesis
14.0K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.0K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
145
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
145


